A repeated-dose evaluation of analgesic use and safety of Dilaudid SR [sustained release] (hydromorphone HCl [hydrochloride]) in patients with chronic cancer pain
Phase of Trial: Phase III
Latest Information Update: 14 Jul 2009
At a glance
- Drugs Hydromorphone (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- Sponsors ALZA Corporation
- 14 Jul 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
- 14 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jul 2009 Actual patient number (463) added as reported by ClinicalTrials.gov.